Showing results (161-170 of 184) with videos related to
Sort By:
Pageof 19
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.Gastroenterology|October 12, 2014
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantationMichael Charlton, Edward Gane, Michael P Manns, et al.Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.Digestive Diseases and Sciences|May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infectionPaul J Clark, Alexander J Thompson, Qianqian Zhu, et al.The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.Pageof 19